LENZ Therapeutics, Inc. Stock OTC Markets
Stocks
GRPH
US52635N1037
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 184M 162M 151M 139M 260M 17.66B 266M 1.79B 701M 8.74B 692M 677M 30.21B | P/E 2026 * |
-1.3x | P/E 2027 * | -1.72x |
|---|---|---|---|---|---|
| Enterprise Value | 184M 162M 151M 139M 260M 17.66B 266M 1.79B 701M 8.74B 692M 677M 30.21B | EV / Sales 2026 * |
9.71x | EV / Sales 2027 * | 2.92x |
| Free-Float |
97.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: LENZ Therapeutics, Inc.
| 1 day | -2.75% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.75% | -4.79% | - | - | 184M | |
| +0.47% | +2.03% | +51.54% | +70.84% | 55.01B | |
| +2.83% | +0.04% | +38.07% | +82.59% | 54.24B | |
| +0.54% | +1.22% | -16.62% | -14.62% | 23.38B | |
| -0.97% | -3.30% | -1.79% | +366.82% | 22.57B | |
| +2.07% | +1.44% | +23.06% | -9.05% | 20.19B | |
| -2.15% | +0.78% | +24.67% | -31.03% | 17.86B | |
| -2.14% | -2.72% | +30.26% | +536.72% | 15.5B | |
| -3.14% | -8.09% | +160.68% | +292.18% | 14.2B | |
| -2.09% | +0.64% | +49.78% | +180.72% | 14.2B | |
| Average | -0.61% | -0.56% | +39.96% | +163.91% | 26.35B | |
| Weighted average by Cap. | +0.39% | -0.20% | +37.26% | +129.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 18.98M 16.68M 15.57M 14.29M 26.75M 1.82B 27.41M 185M 72.2M 900M 71.27M 69.72M 3.11B | 63.18M 55.52M 51.82M 47.56M 89.02M 6.05B 91.22M 614M 240M 2.99B 237M 232M 10.35B |
| Net income | -141M -124M -116M -106M -199M -13.54B -204M -1.37B -538M -6.7B -531M -519M -23.16B | -111M -97.28M -90.81M -83.34M -156M -10.6B -160M -1.08B -421M -5.25B -416M -407M -18.14B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
